Reaping the prevention benefits of highly active antiretroviral treatment: Policy implications of HIV Prevention Trials Network 052

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 111-116

  Forsyth, Andrew D ^a   Valdiserri, Ronald O ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

antiretrovirals; policy; prevention; sexual transmission

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH DISPARITY; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY OF HEALTH CARE; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEALTH POLICY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL PARTNERS;

EID: 84857362322     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834fcff6     Document Type: Review

References (81)

1. Johnson AM, Laga M. Heterosexual transmission of HIV. AIDS 1988; 2 (Suppl 1):S49-S56. (Pubitemid 19042838)
2. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-2185.
3. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
4. Gazzard B. What we know so far. AIDS 1996; 10 (Suppl 1):S3-S7. (Pubitemid 26402203)
5. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10 (Suppl 3):S1-S11. (Pubitemid 26402189)
6. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
7. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:335-343.
8. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIVinfection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121. (Pubitemid 30116436)
9. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
10. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802. (Pubitemid 29415583)
11. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-1976. (Pubitemid 24276382)
12. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
13. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
14. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 2010; 340:c2205.
15. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
16. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
17. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
18. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
19. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
20. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
21. Baggaley RF, Fraser C. Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS 2010; 5:269-276.
22. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature 1991; 350:356-359. (Pubitemid 21912231)
23. Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One 2010; 5:e10991.
24. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
25. Boily MC, Bastos FI, Desai K, Masse B. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis 2004; 31:100-113.
26. Charlebois ED, Havlir DV. 'A bird in the hand...': a commentary on the test and treat approach for HIV. Arch Intern Med 2010; 170:1354-1356.
27. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17:1941-1951. (Pubitemid 37070280)
28. McCormick AW, Walensky RP, Lipsitch M, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44:1115-1122. (Pubitemid 46580284)
29. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493. (Pubitemid 34826854)
30. Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077. (Pubitemid 351769746)
31. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
32. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
33. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet 2010; 376:953-954.
34. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
35. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009; 373:9-11.
36. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505
37. Cambiano V, Rodger AJ, Phillips AN. 'Test-and-treat': the end of the HIV epidemic? Curr Opin Infect Dis 2010; 24:19-26.
38. Grulich AE, Zablotska I. Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol 2010; 39:1064-1065.
39. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-320. (Pubitemid 352020440)
40. Garnett GP, Gazzard B. Risk of HIV transmission in discordant couples. Lancet 2008; 372:270-271. (Pubitemid 352020422)
41. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
42. Barnighausen T. The role of the health system in HIV treatment-as- prevention. AIDS 2010; 24:2741-2742.
43. Cohen T, Corbett EL. Test and treat in HIV: success could depend on rapid detection. Lancet 2011; 378:204-206.
44. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
45. CDC. Results of the expanded HIV testing initiative: 25 jurisdictions, United States, 2007-2010. MMWR 2011; 60:805-810.
46. Moore RD. Epidemiology of HIV infection in the United States: implications for linkage to care. Clin Infect Dis 2011; 52 (Suppl 2):S208-S213.
47. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51:725-731.
48. Cohen MS, Mastro TD, Cates W Jr. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1077; author reply 80-81.
49. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55 (RR-14):1-17; quiz CE1-CE4.
50. Sherr L, Lopman B, Kakowa M, et al. Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. AIDS 2007; 21:851-860. (Pubitemid 46573157)
51. Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS 2010; 5:283-290.
52. Ruark A, Shelton JD, Halperin DT, et al. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078; author reply 80-81.
53. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 2010; 24:2665-2678.
54. Aziz M, Smith KY. Challenges and successes in linking HIV-infected women to care in the United States. Clin Infect Dis 2011; 52 (Suppl 2):S231-S237.
55. Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis 2011; 52 (Suppl 2):S214-S222.
56. Zaller ND, Fu JJ, Nunn A, Beckwith CG. Linkage to care for HIV-infected heterosexual men in the United States. Clin Infect Dis 2011; 52 (Suppl 2): S223-S230.
57. Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 2010; 170:1347-1354.
58. Giordano TP. Retention in HIV Care: what the clinician needs to know. Top Antivir Med 2011; 19:12-16.
59. Glasgow RE, Orleans CT, Wagner EH. Does the chronic care model serve also as a template for improving prevention? Milbank Q 2001; 79:579-612, iv-v. (Pubitemid 33636206)
60. Institute of Medicine. HIV Screening and Access to Care: Health Care System Capacity for Increased HIV Testing and Provision of Care. National Academies Press. Washington, DC: 2011.
61. National Alliance of State and Territorial AIDS Directors. ADAP Watch. National Alliance of State and Territorial AIDS Directors, Publisher. Washington, D.C.; September 23, 2011.
62. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5:e12598.
63. Novitsky V, Wang R, Bussmann H, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission. PLoS One 2010; 5:e10148.
64. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24:907-913.
65. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active ntiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394. (Pubitemid 34184826)
66. Law MG, Woolley I, Templeton DJ, et al. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc 2011; 14:10.
67. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88. (Pubitemid 38402321)
68. de Wit JB, Aggleton P, Myers T, Crewe M. The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. Health Educ Res 2011; 26:381-392.
69. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS 2010; 24:271-277.
70. Persson A. Reflections on the Swiss Consensus Statement in the context of qualitative interviews with heterosexuals living with HIV. AIDS Care 2010; 22:1487-1492.
71. Prestage G, Mao L, Kippax S, et al. Use of viral load to negotiate condom use among gay men in Sydney, Australia. AIDS Behav 2009; 13:645-651.
72. Van de Ven P, Mao L, Fogarty A, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19:179-184. (Pubitemid 40409536)
73. Luchters S, Sarna A, Geibel S, et al. Safer sexual behaviors after 12 months of antiretroviral treatment in Mombasa, Kenya: a prospective cohort. AIDS Patient Care STDS 2008; 22:587-594. (Pubitemid 352040056)
74. Stephenson JM, Imrie J, Davis MM, et al. Is use of antiretroviral therapy among homosexual men associated with increased risk of transmission of HIV infection? Sex Transm Infect 2003; 79:7-10. (Pubitemid 36237819)
75. DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 2010; 50 (Suppl 3):S102-S107.
76. Policy WOoNA. National HIV/AIDS Strategy for the United States. Washington, DC: The White house; 2010.
77. Conway B, Tossonian H. Comprehensive approaches to the diagnosis and treatment of HIV infection in the community: can 'seek and treat' really deliver? Curr Infect Dis Rep 2011; 13:68-74.
78. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011; 15 (Suppl 1):S72-S79.
79. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
80. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378:269-278.
81. Alcorn K. Treatment as prevention: what are the next steps? AIDSmap.com, 2011. url: aidsmap.com/page/1881842. Accessed: July 25, 2011.